Inhibited / diminished sexual desire and loss of orgasm in women

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Ioana Motogna
Keyword(s):  
Sexual Activity ◽  
Sexual Desire ◽  
Sexual Interest ◽  
Desire Disorder

In the specialized literature, sexual desire disorder is approached as a decrease in sexual interest, a lack of fantasies about sexual activity, decreased libido or frigidity. Gutceit believes that “out of 10 women 4 do not feel anything during intercourse and endure it without having the slightest pleasant sensation during friction and without having any idea about the pleasure of ejaculation”, and Debruner even adds that 50% of women are insensitive and one cannot speak of a proper libido.

scholarly journals Testosterone Patch Increases Sexual Activity and Desire in Surgically Menopausal Women with Hypoactive Sexual Desire Disorder

2005 ◽  
Vol 90 (9) ◽  
pp. 5226-5233 ◽  
Author(s):  
James Simon ◽  
Glenn Braunstein ◽  
Lila Nachtigall ◽  
Wulf Utian ◽  
Molly Katz ◽  
...  
Keyword(s):  
Placebo Group ◽  
Sexual Activity ◽  
Sexual Desire ◽  
Estrogen Therapy ◽  
Hypoactive Sexual Desire Disorder ◽  
Double Blind ◽  
End Points ◽  
Parallel Group ◽  
Menopausal Women ◽  
Desire Disorder

Abstract Context: Hypoactive sexual desire disorder (HSDD) is one of the most common sexual problems reported by women, but few studies have been conducted to evaluate treatments for this condition. Objective: The objective of this study was to evaluate the efficacy and safety of a testosterone patch in surgically menopausal women with HSDD. Design: The design was a randomized, double-blind, parallel-group, placebo-controlled, 24-wk study (the Intimate SM 1 study). Setting: The study was performed at private or institutional practices. Patients: The subjects studied were women, aged 26–70 yr, with HSDD after bilateral salpingo-oophorectomy who were receiving concomitant estrogen therapy. Placebo (n = 279) or testosterone 300 μg/d (n = 283) was administered. There were 19 patients who withdrew due to adverse events in the placebo group and 24 in the 300 μg/d testosterone group. Intervention: Testosterone (300 μg/d) or placebo patches were applied twice weekly. Main Outcome Measure(s): The primary end point was the change in the frequency of total satisfying sexual activity at 24 wk. Secondary end points included other sexual functioning end points and safety assessments. Results: At 24 wk, there was an increase from baseline in the frequency of total satisfying sexual activity of 2.10 episodes/4 wk in the testosterone group, which was significantly greater than the change of 0.98 episodes/4 wk in the placebo group (P = 0.0003). The testosterone group also experienced statistically significant improvements in sexual desire and a decrease in distress. The overall safety profile was similar in both treatment groups. Conclusion: In the Intimate SM 1 study, the testosterone patch improved sexual function and decreased distress in surgically menopausal women with HSDD and was well tolerated in this trial.

Validation of the Sexual Interest and Desire Inventory-Female in Hypoactive Sexual Desire Disorder

2010 ◽  
Vol 7 (12) ◽  
pp. 3918-3928 ◽  
Author(s):  
Anita H. Clayton ◽  
David Goldmeier ◽  
Rossella E. Nappi ◽  
Glen Wunderlich ◽  
Diane J. Lewis-D'Agostino ◽  
...  
Keyword(s):  
Sexual Desire ◽  
Sexual Interest ◽  
Hypoactive Sexual Desire Disorder ◽  
Desire Disorder

scholarly journals Flibanserin for hypoactive sexual desire disorder: place in therapy

2017 ◽  
Vol 8 (1) ◽  
pp. 16-25 ◽  
Author(s):  
Faina Gelman ◽  
Jessica Atrio
Keyword(s):  
Sexual Desire ◽  
Mindfulness Meditation ◽  
Sexual Interest ◽  
Behavioral Therapy ◽  
Premenopausal Women ◽  
The United States ◽  
Tribulus Terrestris ◽  
Hypoactive Sexual Desire Disorder ◽  
Therapeutic Modalities ◽  
Desire Disorder

The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.

Cutoff Score of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder

2010 ◽  
Vol 19 (12) ◽  
pp. 2191-2195 ◽  
Author(s):  
Anita H. Clayton ◽  
Robert T. Segraves ◽  
David Bakish ◽  
David Goldmeier ◽  
Jean Tignol ◽  
...  
Keyword(s):  
Sexual Desire ◽  
Sexual Interest ◽  
Cutoff Score ◽  
Hypoactive Sexual Desire Disorder ◽  
Desire Disorder

scholarly journals Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women

Pharmacy ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 71
Author(s):  
Nicole E. Cieri-Hutcherson ◽  
Andrea Jaenecke ◽  
Ajeet Bahia ◽  
Debra Lucas ◽  
Ann Oluloro ◽  
...  
Keyword(s):  
Systematic Review ◽  
Sexual Arousal ◽  
Sexual Desire ◽  
Sexual Interest ◽  
Hypoactive Sexual Desire Disorder ◽  
Female Sexual Arousal ◽  
Arousal Disorder ◽  
Sexual Arousal Disorder ◽  
Female Sexual Arousal Disorder ◽  
Desire Disorder

This systematic review evaluates the efficacy and safety of l-arginine alone or in combination for the treatment of women with hypoactive sexual desire disorder (HSDD) or related conditions, such as female sexual interest/arousal disorder and female sexual arousal disorder. Medline, Embase, International Pharmaceutical Abstracts, Science Direct, and the Cumulative Index to Nursing and Allied Health Literature were searched using keywords “arginine”, “Lady Prelox”, “ArginMax”, “Stronvivo”, “Ristela”, “hypoactive sexual desire disorder”, “female sexual interest arousal disorder”, “female sexual arousal disorder”, “sexual dysfunction”, “sexual behavior”, “dyspareunia”, “libido”, and permutations thereof. Relevant records were retained if they were primary literature, conducted in women with HSDD or related conditions, and published as full text in English. Five randomized controlled trials and two nonrandomized studies met eligibility criteria. Six of the seven studies reported either an increase in the total mean Female Sexual Function Index score or significant increases in multiple domains therein. One study assessed vaginal pulse amplitude and found a statistically significant increase in a combination treatment group compared to placebo. No significant side effects were reported. Four of seven studies had potential risk-of-bias concerns per Cochrane assessments. This systematic review found that combination products containing l-arginine in the form of ArginMax or Lady Prelox may be considered for the treatment of HSDD and related conditions in women regardless of age.

scholarly journals Socio-demographic Determinants of Low Sexual Desire and Hypoactive Sexual Desire Disorder: A Population-based Study in Iran

2020 ◽  
Author(s):  
Zeinab Hamzehgardeshi ◽  
Mina Malary ◽  
Mahmood Moosazadeh ◽  
Soghra Khani ◽  
Mehdi Pourasghar
Keyword(s):  
Sexual Desire ◽  
Sexual Interest ◽  
Population Based ◽  
Reproductive Age ◽  
Hypoactive Sexual Desire Disorder ◽  
Personal Distress ◽  
Iranian Women ◽  
Women Of Reproductive Age ◽  
Low Sexual Desire ◽  
Desire Disorder

Abstract Background: Various socio-demographic factors are determinants of Low Sexual Desire (LSD), but whether these are the determinants of Hypoactive Sexual Desire Disorder (HSDD) are unclear. The aim of this study is to evaluate the Socio-demographic determinants of LSD and HSDD in Iranian women of reproductive age.Methods: This was a population-based, cross-sectional study of 1000 Iranian women of reproductive age (15-49 years) who met the inclusion criteria and were chosen through systematic random sampling from all the healthcare centers in Sari, Iran. LSD was defined as a score no higher than 33 on the Sexual Interest and Desire Inventory-Female (SIDI-F); sexually related personal distress was defined as a score of at least 11.0 on the Female Sexual Distress Scale–Revised (FSDS-R); and HSDD was defined as a combination of these scores. Descriptive statistics were used to describe demographic characteristics while for analyzing grouped variables, chi-square test was applied. Multivariate regression test was also used to adjust the effect of confounding variables. Results: The mean score of sexual interest/desire among women who referred to healthcare centers in the city of Sari is estimated as 30.6±10.5. After adjusting the effect of the confounder variables by logistic regression multivariate analysis, the age at first intercourse, the length of time spent in marriage, and the level of satisfaction with income were variables significantly associated with LSD and HSDD (P < .01). Although increasing individual′s age (P < .001) and body mass index (P < .01) were predictors of LSD in women, HSDD was not statistically significant.Conclusion: There are some factors that are associated with LSD in women but are not related to HSDD. In other words, some factors associated with LSD do not cause personal distress which are one of the criteria necessary for HSDD.

Sign in / Sign up

Export Citation Format

Share Document